Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Pay for Performance Versus Patient-Centered Care in Psoriasis: How Can I Do It All?

Premiere Date: Monday, January 24, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, January 24, 2023
Note: Credit Is No Longer Available


April W. Armstrong, MD, MPHApril W. Armstrong, MD, MPH (Moderator)
Associate Dean, Clinical Research
Professor of Dermatology
Director, Clinical Research Support, Southern California CTSI
Keck School of Medicine
University of Southern California
Los Angeles, CA

Kenneth B. Gordon, MDKenneth B. Gordon, MD 
Professor and Thomas J. Russell Family/Milwaukee Community Dermatologist Chair
Department of Dermatology
Medical College of Wisconsin
Milwaukee, WI

Statement of Need

Pay for performance in psoriasis (PsO) care is a reimbursement model based on the percentage of patients receiving systemic medication who meet minimal physician- or patient-reported disease activity levels. This merit-based program measures clinician performance against metric-driven outcomes, proven best practices, and patient satisfaction. However, there are many challenges associated with this model that dermatologists and their staff have to address, particularly when treating patients with more complex PsO. This begins with accurate diagnosis and assessment of disease severity and burden, translating new PsO guidelines, and ensuring that patients receive appropriate systemic treatment to establish and maintain minimal disease activity levels. Adherence to treatment regimens is critical for optimal outcomes in PsO management, improved quality of life (QoL), and patient satisfaction. The use of validated measuring scores and patient-reported outcomes in PsO treatment and management may help to enhance disease assessment, patient engagement, and treatment adherence in both in-person and teledermatology care for PsO.

This CMEOCast podcast will focus on the measuring tools that allow for accurate assessment and diagnosis, the factors that are associated with patient perspectives regarding the burden of PsO, implementing best practice guidelines and recommendations, and strategies for engaging patients in discussions about their PsO treatment regimen and goals to improve medication adherence, therapeutic outcomes, and QoL.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Integrate assessment tools for PsO disease activity to guide treatment decisions, assess treatment response, and measure QoL.
  • Apply recommendations from the AAD/NPF guidelines to treatment decisions for patients with moderate-to-severe PsO.
  • Work collaboratively with patients to integrate self-management tools into their PsO care plan to increase patient activation and improve QoL.

Financial Support

Supported by an educational grant from Celgene Corporation.

Target Audience

Dermatologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Armstrong reports the following financial relationships:

Consultant: AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim; Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Sun Pharma; and UCB Pharma

Grants: Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Leo Pharma Inc.; and Pfizer Inc.

Dr. Gordon reports the following financial relationships:

Grants: Eli Lilly and Company

Research Support: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and UCB, Inc.

Consultant: AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics; Arena Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Incyte; Janssen-Kyowa Kakko Kirin Co Ltd.; LEO Pharma Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi Genzyme; Sun Pharmaceutical Industries Inc; and UCB, Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • S. Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Noreen Iftikhar, MD (planning committee)
  • Susan Perry (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download